Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-02-25Clinical Trial Update: Study of rSIFN-co for Patients With Advanced Solid Tumors [Phase 1]
A Phase 1 clinical trial of rSIFN-co for advanced solid tumors has been terminated, involving malignancies including melanoma, kidney cancer…
-
CLINICAL_TRIALS withdrawal · 2025-02-10Clinical Trial Update: Neuroendocrine and Adrenal Tumors
The clinical trial NCT04432532 investigating neuroendocrine tumors and adrenal tumors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-08-23Clinical Trial Update: 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
The clinical trial evaluating 68Ga DOTA-TATE PET/CT in somatostatin receptor–positive tumors is no longer available.
-
CLINICAL_TRIALS withdrawal · 2016-11-08Clinical Trial Update: Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
A clinical trial evaluating Gallium-68 DOTATOC for the management of Neuroendocrine tumors is no longer available.
-
CLINICAL_TRIALS withdrawal · 2016-11-02Clinical Trial Update: 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
The expanded access trial of the radiopharmaceutical 68Ga-DOTATOC for imaging neuroendocrine tumors is no longer available.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2016-06-21Clinical Trial Update: 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) [Phase 2]
A Phase 2 trial of 90Y DOTA/Retinoic Acid for neuroblastoma and neuroendocrine tumors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-07-22Clinical Trial Update: Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease [Phase 1]
A Phase 1 trial of TheraSphere in combination with Everolimus for neuroendocrine tumors with liver-dominant disease has been withdrawn.